Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 185

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications

Open access
Isidori, Andrea M., Graziadio, Chiara, Paragliola, Rosa Maria, Cozzolino, Alessia, Ambrogio, Alberto G., Colao, Annamaria, Corsello, Salvatore M., Pivonello, Rosario · 2015 · Journal of Hypertension

Abstract

Cushing's syndrome is associated with increased mortality, mainly due to cardiovascular complications, which are sustained by the common development of systemic arterial hypertension and metabolic syndrome, which partially persist after the disease remission. Cardiovascular diseases and hypertension associated with endogenous hypercortisolism reveal underexplored peculiarities. The use of exogenous corticosteroids also impacts on hypertension and cardiovascular system, especially after prolonged treatment. The mechanisms involved in the development of hypertension differ, whether glucocorticoid excess is acute or chronic, and the source endogenous or exogenous, introducing inconsistencies among published studies. The pleiotropic effects of glucocorticoids and the overlap of the several regulatory mechanisms controlling blood pressure suggest that a rigorous comparison of in-vivo and in-vitro studies is necessary to draw reliable conclusions. This review, developed during the first 'Altogether to Beat Cushing's syndrome' workshop held in Capri in 2012, evaluates the most important peculiarities of hypertension associated with CS, with a particular focus on its pathophysiology. A critical appraisal of most significant animal and human studies is compared with a systematic review of the few available clinical trials. A special attention is dedicated to the description of the clinical features and cardiovascular damage secondary to glucocorticoid excess. On the basis of the consensus reached during the workshop, a pathophysiology-oriented therapeutic algorithm has been developed and it could serve as a first attempt to rationalize the treatment of hypertension in Cushing's syndrome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/hjh.0000000000000415

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 121

  1. Graversen, 2012, Mortality in Cushings syndrome: a systematic review and meta-analysis., Eur J Intern Med, 23, 278, 10.1016/j.ejim.2011.10.013 · DOI
  2. Lambert, 2013, Predictors of mortality and long-term outcomes in treated Cushings disease: a study of 346 patients., J Clin Endocrinol Metab, 98, 1022, 10.1210/jc.2012-2893 · DOI · Paper page
  3. Bertoia, 2012, Implications of new hypertension guidelines in the United States., Hypertension, 60, 639, 10.1161/HYPERTENSIONAHA.112.193714 · DOI
  4. Imai, 1988, Altered circadian blood pressure rhythm in patients with Cushings syndrome., Hypertension, 12, 11, 10.1161/01.HYP.12.1.11 · DOI · Paper page
  5. Pecori, 2007, Circadian blood pressure profile in patients with active Cushings disease and after long-term cure., Horm Metab Res, 39, 908, 10.1055/s-2007-992813 · DOI
  6. Walker, 1993, Deficient inactivation of cortisol by 11 beta-hydroxysteroid dehydrogenase in essential hypertension., Clin Endocrinol (Oxf), 39, 221, 10.1111/j.1365-2265.1993.tb01778.x · DOI · Paper page
  7. Watt, 1992, Abnormalities of glucocorticoid metabolism and the renin-angiotensin system: a four-corners approach to the identification of genetic determinants of blood pressure., J Hypertens, 10, 473, 10.1097/00004872-199205000-00011 · DOI · Paper page
  8. Van Staa, 2000, Use of oral corticosteroids in the United Kingdom., QJM, 93, 105, 10.1093/qjmed/93.2.105 · DOI · Paper page
  9. Imai, 1989, Exogenous glucocorticoid eliminates or reverses circadian blood pressure variations., J Hypertens, 7, 113, 10.1097/00004872-198902000-00006 · DOI
  10. Wei, 2004, Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease., Ann Intern Med, 141, 764, 10.7326/0003-4819-141-10-200411160-00007 · DOI · Paper page
  11. Souverein, 2004, Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study., Heart, 90, 859, 10.1136/hrt.2003.020180 · DOI · Paper page
  12. Devoe, 1997, Long-term outcome in children and adolescents after transsphenoidal surgery for Cushings disease., J Clin Endocrinol Metab, 82, 3196
  13. Lodish, 2009, Blood pressure in pediatric patients with Cushing syndrome., J Clin Endocrinol Metab, 94, 2002, 10.1210/jc.2008-2694 · DOI
  14. Feelders, 2012, The burden of Cushings disease: clinical and health-related quality of life aspects., Eur J Endocrinol, 167, 311, 10.1530/EJE-11-1095 · DOI · Paper page
  15. Rossi, 2011, Drug-related hypertension and resistance to antihypertensive treatment: a call for action., J Hypertens, 29, 2295, 10.1097/HJH.0b013e32834c465d · DOI
  16. Hammer, 2006, Cortisol metabolism in hypertension., Best Pract Res Clin Endocrinol Metab, 20, 337, 10.1016/j.beem.2006.07.001 · DOI
  17. Magiakou, 1997, Blood pressure in children and adolescents with Cushings syndrome before and after surgical care., J Clin Endocrinol Metab, 82, 1734
  18. Dias, 2006, The discriminatory value of the low-dose dexamethasone suppression test in the investigation of paediatric Cushings syndrome., Horm Res, 65, 159
  19. Storr, 2004, Prepubertal Cushings disease is more common in males, but there is no increase in severity at diagnosis., J Clin Endocrinol Metab, 89, 3818, 10.1210/jc.2003-031531 · DOI
  20. Ulick, 1992, Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome., J Clin Endocrinol Metab, 74, 963
  21. Saruta, 1986, Multiple factors contribute to the pathogenesis of hypertension in Cushings syndrome., J Clin Endocrinol Metab, 62, 275, 10.1210/jcem-62-2-275 · DOI · Paper page
  22. Ritchie, 1990, Studies on the pathogenesis of hypertension in Cushings disease and acromegaly., Q J Med, 76, 855
  23. Yasuda, 1994, Exaggerated blood pressure response to angiotensin II in patients with Cushings syndrome due to adrenocortical adenoma., Eur J Endocrinol, 131, 582, 10.1530/eje.0.1310582 · DOI
  24. Fuller, 2005, Mechanisms of mineralocorticoid action., Hypertension, 46, 1227, 10.1161/01.HYP.0000193502.77417.17 · DOI · Paper page
  25. Stewart, 1995, 11 beta-Hydroxysteroid dehydrogenase activity in Cushings syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome., J Clin Endocrinol Metab, 80, 3617
  26. Isidori, 2006, The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up., J Clin Endocrinol Metab, 91, 371, 10.1210/jc.2005-1542 · DOI · Paper page
  27. Whitworth, 1989, The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume., J Hypertens, 7, 537, 10.1097/00004872-198907000-00005 · DOI
  28. Williamson, 1996, Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans., J Hypertens Suppl, 14, S37
  29. Bailey, 2009, Mineralocorticoid and glucocorticoid receptors stimulate epithelial sodium channel activity in a mouse model of Cushing syndrome., Hypertension, 54, 890, 10.1161/HYPERTENSIONAHA.109.134973 · DOI
  30. Nieman, 1985, Successful treatment of Cushings syndrome with the glucocorticoid antagonist RU 486., J Clin Endocrinol Metab, 61, 536, 10.1210/jcem-61-3-536 · DOI · Paper page
  31. McMahon, 2001, Recent studies with eplerenone, a novel selective aldosterone receptor antagonist., Curr Opin Pharmacol, 1, 190, 10.1016/S1471-4892(01)00022-4 · doi:10.1016/s1471-4892(01)00022-4
  32. Rickard, 2012, Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosteronesalt-mediated inflammation and cardiac fibrosis., Hypertension, 60, 1443, 10.1161/HYPERTENSIONAHA.112.203158 · DOI
  33. Nagata, 2006, Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats., Hypertension, 47, 656, 10.1161/01.HYP.0000203772.78696.67 · DOI · Paper page
  34. Mannelli, 1994, Adrenal medulla secretion in Cushings syndrome., J Clin Endocrinol Metab, 78, 1331
  35. Heaney, 1999, Increased pressor response to noradrenaline in pituitary dependent Cushings syndrome., Clin Endocrinol (Oxf), 51, 293, 10.1046/j.1365-2265.1999.00766.x · DOI
  36. McKnight, 1995, Blood pressure responses to phenylephrine infusions in subjects with Cushings syndrome., J Hum Hypertens, 9, 855
  37. Jyotsna, 2011, Effect of Cushings syndrome: endogenous hypercortisolemia on cardiovascular autonomic functions., Auton Neurosci, 160, 99, 10.1016/j.autneu.2010.11.007 · DOI
  38. Ruschitzka, 2001, Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide., Circulation, 103, 3129, 10.1161/01.CIR.103.25.3129 · DOI
  39. Kirilov, 2003, Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushings syndrome., Eur J Endocrinol, 149, 549, 10.1530/eje.0.1490549 · DOI
  40. Kelly, 2000, Role of erythropoietin in cortisol-induced hypertension., J Hum Hypertens, 14, 195, 10.1038/sj.jhh.1000959 · DOI
  41. Smith, 1994, Regulation of sodium-calcium exchanger by glucocorticoids and growth factors in vascular smooth muscle., J Biol Chem, 269, 27527, 10.1016/S0021-9258(18)47016-0 · doi:10.1016/s0021-9258(18)47016-0
  42. Radomski, 1990, Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells., Proc Natl Acad Sci U S A, 87, 10043, 10.1073/pnas.87.24.10043 · DOI · Paper page
  43. Wallerath, 1999, Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension., Proc Natl Acad Sci U S A, 96, 13357, 10.1073/pnas.96.23.13357 · DOI · Paper page
  44. Simmons, 1996, Glucocorticoids regulate inducible nitric oxide synthase by inhibiting tetrahydrobiopterin synthesis and L-arginine transport., J Biol Chem, 271, 23928, 10.1074/jbc.271.39.23928 · DOI · Paper page
  45. Kelly, 1998, The nitric oxide system and cortisol-induced hypertension in humans., Clin Exp Pharmacol Physiol, 25, 945, 10.1111/j.1440-1681.1998.tb02349.x · DOI
  46. Rizzoni, 2006, Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism., J Clin Endocrinol Metab, 91, 2638, 10.1210/jc.2006-0101 · DOI
  47. Limbourg, 2002, Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids., J Clin Invest, 110, 1729, 10.1172/JCI0215481 · doi:10.1172/jci0215481 · Paper page
  48. Serarslan, 2010, Protective effects of tadalafil on experimental spinal cord injury in rats., J Clin Neurosci, 17, 349, 10.1016/j.jocn.2009.03.036 · doi:10.1016/j.jocn.2009.03.036
  49. Colao, 2012, Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging., Circulation, 125, 2323, 10.1161/CIRCULATIONAHA.111.063412 · DOI · Paper page
  50. Knoepfelmacher, 1998, Effect of corticotrophin-releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushings disease., Clin Endocrinol (Oxf), 49, 77, 10.1046/j.1365-2265.1998.00479.x · DOI
  51. Knoepfelmacher, 1997, Resistance to vasopressin action on the kidney in patients with Cushings disease., Eur J Endocrinol, 137, 162, 10.1530/eje.0.1370162 · DOI
  52. Yamaji, 1988, Plasma levels of atrial natriuretic hormone in Cushings syndrome., J Clin Endocrinol Metab, 67, 348, 10.1210/jcem-67-2-348 · doi:10.1210/jcem-67-2-348
  53. Sala, 2001, Blunted vascular and renal effects of exogenous atrial natriuretic peptide in patients with cushings disease., J Clin Endocrinol Metab, 86, 1957
  54. Yasunari, 1990, Glucocorticoids and atrial natriuretic factor receptors on vascular smooth muscle., Hypertension, 16, 581, 10.1161/01.HYP.16.5.581 · DOI
  55. Fujio, 1989, Cardiovascular, renal and endocrine effects of alpha-human atrial natriuretic peptide in patients with Cushings syndrome and primary aldosteronism., J Hypertens, 7, 653, 10.1097/00004872-198908000-00009 · doi:10.1097/00004872-198908000-00009
  56. Axelrod, 1983, Inhibition of prostacyclin production mediates permissive effect of glucocorticoids on vascular tone. Perturbations of this mechanism contribute to pathogenesis of Cushings syndrome and Addisons disease., Lancet, 1, 904, 10.1016/S0140-6736(83)91330-2 · DOI
  57. Shimamoto, 1995, Significance of renal kininases in patients with Cushings syndrome., Clin Exp Hypertens, 17, 1173, 10.3109/10641969509037402 · DOI
  58. van Raalte, 2009, Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options Eur J Clin I, nvest, 39, 81
  59. Giordano, 2012, Glucose metabolism in patients with subclinical Cushings syndrome., Endocrine, 41, 415, 10.1007/s12020-012-9628-9 · DOI
  60. Huang, 2002, Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator-activated receptor-alpha ligands, glucocorticoids, and insulin., Diabetes, 51, 276, 10.2337/diabetes.51.2.276 · DOI · Paper page
  61. Patel, 2011, LXRbeta is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice., J Clin Invest, 121, 431, 10.1172/JCI41681 · DOI
  62. Albiger, 2006, Patients with Cushings syndrome have increased intimal media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors., Horm Metab Res, 38, 405, 10.1055/s-2006-944545 · DOI
  63. Giordano, 2014, Is diabetes in Cushings syndrome only a consequence of hypercortisolism Eur J E, ndocrinol, 170, 311
  64. Colao, 1999, Persistence of increased cardiovascular risk in patients with Cushings disease after five years of successful cure., J Clin Endocrinol Metab, 84, 2664
  65. Zacharieva, 2004, Vascular endothelial growth factor (VEGF), prostaglandin E2(PGE2) and active renin in hypertension of adrenal origin., J Endocrinol Invest, 27, 742, 10.1007/BF03347516 · doi:10.1007/bf03347516
  66. Bender, 2013, Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease D, iabetes, 62, 313
  67. Gatenby, 2010, The role of IGF-1 resistance in obesity and type 2 diabetes-mellitus-related insulin resistance and vascular disease., Expert Opin Ther Targets, 14, 1333, 10.1517/14728222.2010.528930 · DOI
  68. Parati, 2012, Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (COoperation in Scientific and Technological research) ACTION B26 on obstructive sleep apnea., J Hypertens, 30, 633, 10.1097/HJH.0b013e328350e53b · DOI · Paper page
  69. Bottini, 2003, Sleep apnea syndrome in endocrine diseases., Respiration, 70, 320, 10.1159/000072019 · DOI
  70. Shipley, 1992, Sleep architecture and sleep apnea in patients with Cushings disease., Sleep, 15, 514, 10.1093/sleep/15.6.514 · DOI
  71. Venkatram, 2014, Unusual triad of obstructive sleep apnea, uncontrolled hypertension, and severe hypokalemia due to ectopic adrenocorticotropic secretion., J Bronchology Interv Pulmonol, 21, 158, 10.1097/LBR.0000000000000060 · doi:10.1097/lbr.0000000000000060
  72. Zanchetti, 2012, What should be learnt about the management of obstructive sleep apnea in hypertension J H, ypertens, 30, 669, 10.1097/HJH.0b013e328351b988 · DOI
  73. Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies., Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8 · DOI · Paper page
  74. Etxabe, 1994, Morbidity and mortality in Cushings disease: an epidemiological approach., Clin Endocrinol (Oxf), 40, 479, 10.1111/j.1365-2265.1994.tb02486.x · DOI · Paper page
  75. Clayton, 2011, Mortality and morbidity in Cushings disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature., J Clin Endocrinol Metab, 96, 632, 10.1210/jc.2010-1942 · DOI · Paper page
  76. Coylewright, 2008, Menopause and hypertension: an age-old debate., Hypertension, 51, 952, 10.1161/HYPERTENSIONAHA.107.105742 · DOI · Paper page
  77. Zacharieva, 2004, Circadian blood pressure profile in patients with Cushings syndrome before and after treatment., J Endocrinol Invest, 27, 924, 10.1007/BF03347534 · doi:10.1007/bf03347534
  78. Gagliardi, 2014, ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia., J Clin Endocrinol Metab, 99, E1784, 10.1210/jc.2014-1265 · DOI · Paper page
  79. Varughese, 2014, Hypercortisolism in obesity-associated hypertension., Curr Hypertens Rep, 16, 443, 10.1007/s11906-014-0443-y · DOI
  80. Muiesan, 2003, Left ventricular structural and functional characteristics in Cushings syndrome., J Am Coll Cardiol, 41, 2275, 10.1016/S0735-1097(03)00493-5 · DOI · Paper page
  81. Toja, 2012, Clinical relevance of cardiac structure and function abnormalities in patients with Cushings syndrome before and after cure., Clin Endocrinol (Oxf), 76, 332, 10.1111/j.1365-2265.2011.04206.x · DOI
  82. Ainscough, 2009, Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction., Cardiovasc Res, 81, 592, 10.1093/cvr/cvn230 · DOI
  83. Mihailidou, 2009, Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction., Hypertension, 54, 1306, 10.1161/HYPERTENSIONAHA.109.136242 · DOI · Paper page
  84. Yiu, 2012, Increased myocardial fibrosis and left ventricular dysfunction in Cushings syndrome., Eur J Endocrinol, 166, 27, 10.1530/EJE-11-0601 · DOI
  85. Alexandraki, 2011, Specific electrocardiographic features associated with Cushings disease., Clin Endocrinol (Oxf), 74, 558, 10.1111/j.1365-2265.2011.03975.x · DOI
  86. Fallo, 2009, Cardiovascular autonomic function in Cushings syndrome., J Endocrinol Invest, 32, 41, 10.1007/BF03345677 · DOI
  87. De Leo, 2010, Cardiovascular disease in Cushings syndrome: heart versus vasculature., Neuroendocrinology, 92, 50, 10.1159/000318566 · DOI
  88. Akaza, 2010, Endothelial dysfunction aassociated with hypercortisolism is reversible in Cushings syndrome., Endocr J, 57, 245, 10.1507/endocrj.K09E-260 · DOI
  89. Baykan, 2007, Impairment of flow-mediated vasodilatation of brachial artery in patients with Cushings Syndrome., Endocrine, 31, 300, 10.1007/s12020-007-0033-8 · DOI
  90. Prazny, 2008, Impaired microvascular reactivity and endothelial function in patients with Cushings syndrome: influence of arterial hypertension., Physiol Res, 57, 13, 10.33549/physiolres.931126 · DOI
  91. Molnar, 2008, Glucocorticoid-related signaling effects in vascular smooth muscle cells., Hypertension, 51, 1372, 10.1161/HYPERTENSIONAHA.107.105718 · DOI
  92. van den Meiracker, 2008, Corticosteroid-dependent, aldosterone-independent mineralocorticoid-receptor activation in the heart., J Hypertens, 26, 1307, 10.1097/HJH.0b013e328305e195 · DOI
  93. Koh, 2000, Increased urinary albumin excretion in Cushings syndrome: remission after correction of hypercortisolaemia., Clin Endocrinol (Oxf), 52, 349, 10.1046/j.1365-2265.2000.00917.x · DOI
  94. Faggiano, 2002, Evaluation of circulating levels and renal clearance of natural amino acids in patients with Cushings disease., J Endocrinol Invest, 25, 142, 10.1007/BF03343978 · DOI
  95. Faggiano, 2003, Nephrolithiasis in Cushings disease: prevalence, etiopathogenesis, and modification after disease cure., J Clin Endocrinol Metab, 88, 2076, 10.1210/jc.2002-021494 · DOI
  96. Biller, 2009, The Network for the Enhancement of Endocrinology and Oncology Knowledge: a case-based consideration of current practice in Cushings disease and acromegaly., Best Pract Res Clin Endocrinol Metab, 23, S1, 10.1016/S1521-690X(09)00149-3 · DOI
  97. Hammer, 2004, Transsphenoidal microsurgery for Cushings disease: initial outcome and long-term results., J Clin Endocrinol Metab, 89, 6348, 10.1210/jc.2003-032180 · DOI · Paper page
  98. Lindholm, 2001, Incidence and late prognosis of cushings syndrome: a population-based study., J Clin Endocrinol Metab, 86, 117
  99. Chow, 2008, Bilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushings syndrome: a review of the Mayo Clinic experience., Clin Endocrinol (Oxf), 68, 513, 10.1111/j.1365-2265.2007.03082.x · DOI
  100. Bassareo, 2010, Increased arterial rigidity in children affected by Cushings syndrome after successful surgical cure., Cardiol Young, 20, 610, 10.1017/S1047951110000727 · DOI
  101. Nieman, 2002, Medical therapy of Cushings disease., Pituitary, 5, 77, 10.1023/A:1022308429992 · DOI · Paper page
  102. Pecori Giraldi, 2012, Potential role for retinoic acid in patients with Cushings disease., J Clin Endocrinol Metab, 97, 3577, 10.1210/jc.2012-2328 · DOI
  103. Donadille, 2010, Management of Cushings syndrome due to ectopic adrenocorticotropin secretion with 1,ortho-1, para-dichloro-diphenyl-dichloro-ethane: findings in 23 patients from a single center., J Clin Endocrinol Metab, 95, 537, 10.1210/jc.2009-1317 · DOI
  104. Pivonello, 2009, The medical treatment of Cushings disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery., J Clin Endocrinol Metab, 94, 223, 10.1210/jc.2008-1533 · DOI · Paper page
  105. Pivonello, 2014, Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushings disease: results from a Phase III study., Clin Endocrinol (Oxf), 81, 408, 10.1111/cen.12431 · DOI
  106. Feelders, 2010, Pasireotide alone or with cabergoline and ketoconazole in Cushings disease., N Engl J Med, 362, 1846, 10.1056/NEJMc1000094 · DOI · Paper page
  107. Bertagna, 2014, LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushings disease: results from a multicenter, proof-of-concept study., J Clin Endocrinol Metab, 99, 1375, 10.1210/jc.2013-2117 · DOI · Paper page
  108. Castinetti, 2012, The use of the glucocorticoid receptor antagonist mifepristone in Cushings syndrome., Curr Opin Endocrinol Diabetes Obes, 19, 295, 10.1097/MED.0b013e32835430bf · DOI
  109. Fallo, 1993, Response of hypertension to conventional antihypertensive treatment andor steroidogenesis inhibitors in Cushings syndrome., J Intern Med, 234, 595, 10.1111/j.1365-2796.1993.tb01018.x · DOI
  110. Mancia, 2014, Target blood pressure in elderly hypertensive patients and in patients with diabetes mellitus., J Hypertens, 32, 1551, 10.1097/HJH.0000000000000275 · DOI
  111. da MF, Murray, 2011, Overt immune dysfunction after Cushings syndrome remission: a consecutive case series and review of the literature., J Clin Endocrinol Metab, 96, E1670, 10.1210/jc.2011-1317 · DOI
  112. Zanchetti, 2002, Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial., Circulation, 106, 2422, 10.1161/01.CIR.0000039288.86470.DD · DOI · Paper page
  113. Thompson, 2011, Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis., J Am Med Assoc, 305, 913, 10.1001/jama.2011.250 · DOI · Paper page
  114. Greenberg, 2000, Diuretic complications., Am J Med Sci, 319, 10, 10.1016/S0002-9629(15)40676-7 · DOI
  115. Mason, 2005, The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension., J Hypertens, 23, 1777, 10.1097/01.hjh.0000177537.91527.09 · DOI
  116. Wolfgram, 2013, Hydrochlorothiazide compared to chlorthalidone in reduction of urinary calcium in patients with kidney stones., Urolithiasis, 41, 315, 10.1007/s00240-013-0568-5 · doi:10.1007/s00240-013-0568-5
  117. Vigen, 2011, Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion Int Urol N, ephrol, 43, 813
  118. Chapman, 2008, Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial., Circulation, 118, 42, 10.1161/CIRCULATIONAHA.107.737957 · DOI
  119. Dahlof, 2005, Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial., Lancet, 366, 895, 10.1016/S0140-6736(05)67185-1 · DOI · Paper page
  120. Mancia, 2006, New-onset diabetes and antihypertensive drugs., J Hypertens, 24, 3, 10.1097/01.hjh.0000194119.42722.21 · DOI · Paper page
  121. Laurent, 2012, New drugs, procedures, and devices for hypertension., Lancet, 380, 591, 10.1016/S0140-6736(12)60825-3 · DOI

Cited by

See all 185

Metadata

Authors
Isidori, A. M., Graziadio, C., Paragliola, R. M., Cozzolino, A., Ambrogio, A. G., Colao, A., Corsello, S. M., & Pivonello, R.
Venue
Journal of Hypertension
Published
2015-01
Volume
33
Issue
1
Pages
44-60
ISSN
0263-6352 (ISSN-L)
OpenAlex
W1979363038
Cited by
185
References
24
FWCI
6.70
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications. https://app.cochat.ai/papers/10.1097/hjh.0000000000000415
The paper
Isidori, A. M., Graziadio, C., Paragliola, R. M., Cozzolino, A., Ambrogio, A. G., Colao, A., Corsello, S. M., & Pivonello, R. (2015). The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications. Journal of Hypertension. https://doi.org/10.1097/hjh.0000000000000415

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.